Leerink Partnrs Issues Optimistic Estimate for RARE Earnings
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Free Report) – Investment analysts at Leerink Partnrs boosted their Q2 2025 earnings per share estimates for shares of Ultragenyx Pharmaceutical in a note issued to investors on Wednesday, May 7th. Leerink Partnrs analyst J. Schwartz now forecasts that the biopharmaceutical company will earn ($1.29) per share for the quarter, […]
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Free Report) – Investment analysts at Leerink Partnrs boosted their Q2 2025 earnings per share estimates for shares of Ultragenyx Pharmaceutical in a note issued to investors on Wednesday, May 7th. Leerink Partnrs analyst J. Schwartz now forecasts that the biopharmaceutical company will earn ($1.29) per share for the quarter, […]
